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ABSTRACT
Rationale: The A Tool to Assess Quality of Life in
Idiopathic Pulmonary Fibrosis (ATAQ-IPF) was
developed in the USA to assess health-related quality
of life in patients with IPF. It is likely that some of the
original ATAQ-IPF items perform differently when
applied in different countries. This paper reports
results of a study conducted to identify the need to
refine the content of the ATAQ-IPF to minimise cross-
country bias between the USA and the UK.
Methods: The ATAQ-IPF and other study measures
were completed by patients attending specialist IPF
clinics in the USA and UK. Rasch analysis was used to
determine which items performed differently across
countries (USA vs UK) and refine the original ATAQ-IPF
to an instrument without cross-country bias
(ATAQ-IPF-cA). Preliminary validation of the modified
instrument was examined by assessing correlations
between ATAQ-IPF-cA scores and scores from
dyspnoea-specific patient-reported outcome (PRO)
measures.
Results: 139 patients with IPF (USA=74; UK=65)
participated in the study. A total of 41 items and 4
domains were removed from the original, 86-item
instrument to yield the 43 items and 10 domains of
the ATAQ-IPF-cA. Each domain had good fit to the
Rasch model, internal consistency was comparable to
the corresponding domains for the original ATAQ-IPF,
and validity was supported by significant correlations
between its scores and scores from dyspnoea-specific
PROs.
Conclusions: The reliability and validity of the
substantially shortened ATAQ-IPF-cA are acceptable
and comparable to the original instrument. We
recommend use of the ATAQ-IPF-cA in IPF studies in
which participants are enrolled from the USA and UK.
INTRODUCTION
Idiopathic pulmonary ﬁbrosis (IPF) is a life-
shortening disease (median survival is
5 years) characterised histologically by pro-
gressive scarring of the lung parenchyma
and symptomatically by dyspnoea and
nagging cough.1 2 Given the limitations and
burdens IPF imposes on patients (and their
families and loved ones), it is not surprising
that quality of life (QOL) is markedly
impaired for patients with this disease.3 4 An
IPF-speciﬁc instrument to assess
health-related quality of life (HRQL) has not
been used as an outcome measure in any
drug trial for IPF, but generic QOL tools (eg,
the Medical Outcomes Study Short-Form
36-item or SF-36)5 and obstructive lung
disease-speciﬁc instruments (The St George’s
Respiratory Questionnaire)6 have, and
responses on them reveal that impairments
in HRQL are driven by symptoms (dyspnoea,
cough and fatigue) and, in particular, by
dyspnoea-imposed limitations on physical
activities.
A Tool to Assess Quality of Life in
Idiopathic Pulmonary Fibrosis (ATAQ-IPF),
an IPF-speciﬁc instrument to assess HRQL,
was designed, and the ﬁrst study to generate
validation data for it was performed, in a
sample of patients with IPF in the USA.7
KEY MESSAGES
▸ Idiopathic pulmonary fibrosis (IPF) shortens the
lives of patients while impairing their quality of
life.
▸ Items on patient-reported outcome (PRO) mea-
sures developed in one country may not
perform equally well in other countries. If a PRO
is revised by deleting items that function differ-
ently across countries, the performance of the
new, revised PRO will have better performance
in multinational study samples.
▸ In a cohort of participants with IPF from the
USA and UK, we administered the original
ATAQ-IPF, identified differentially and otherwise
poorly functioning items and deleted them to
develop a cross-Atlantic version of an ATAQ-IPF
(the ATAQ-IPF-cA).
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Internal consistency (IC) was acceptable for all but the
Relationships domain (for which Cronbach’s α was
0.61). There were signiﬁcant correlations between
domain scores and markers of IPF severity, including
pulmonary function, gas exchange and functional cap-
acity; and as hypothesised, scores from most domains
indicated greater impairment in HRQL among partici-
pants using supplemental oxygen compared with those
not needing supplemental oxygen. ATAQ-IPF has been
—and is currently being—used in research conducted
in the USA and UK predominantly, although whether
ATAQ-IPF performs similarly in samples from different
countries is unknown. This raises concerns about the
utility of the questionnaire when used internationally.
Given that the ATAQ-IPF is predominantly being used in
studies conducted in the USA and UK, respondents in
these countries were selected for this analysis. Some evi-
dence suggests responses to HRQL questionnaires vary
across countries, thus raising concern about their world-
wide utility.8 It is likely that some ATAQ-IPF items
possess weak measurement properties when the instru-
ment is administered to patients from countries other
than the USA. Removing such items would generate a
version of the ATAQ-IPF that is more appropriate for
patients with IPF outside the USA (or in a mixed sample
with participants hailing from the USA and UK). This
paper reports results of a study conducted to identify
the need to reﬁne the content of the ATAQ-IPF to min-
imise cross-country bias between the USA and UK.
METHODS
Overview and study sample
This was a cross-sectional study for which samples were
recruited from specialist respiratory and interstitial lung
disease clinics in the USA and UK. Participants com-
pleted patient-reported outcome (PRO) measures—
including ATAQ-IPF once. Response data from
ATAQ-IPF were subjected to an item deletion algorithm
to yield a cross-Atlantic version of the instrument
(ATAQ-IPF-cA). Rasch analysis was used in this algorithm
to identify items for deletion because they performed
differently across countries (USA vs UK). This differen-
tial performance—or differential item functioning
(DIF)—can be tested for statistical signiﬁcance with
Rasch analytic methods. Items that survived the deletion
algorithm compose the ATAQ-IPF-cA. We examined asso-
ciations between ATAQ-IPF-cA scores and, because dys-
pnoea is the main driver of HRQL in IPF, scores from
dyspnoea-speciﬁc PROs.
Demographic and clinical details were collected from
medical records at the time of questionnaire comple-
tion. Comparisons between subgroups were made by
using t tests for continuous variables and the
Mantel-Haenszel, χ2 or Fisher’s exact test as appropriate.
Forced vital capacity (FVC) and diffusing capacity of the
lung for carbon monoxide (DLCO) were measured in
accordance with American Thoracic Society (ATS)
guidelines9–11 and expressed as percentages of the
gender, age and height-adjusted predicted values (ie,
FVC%, DLCO%). Values obtained closest to the time of
ATAQ-IPF and dyspnoea PRO completion are reported;
however, because the majority of participants from the
UK did not perform FVC or DLCO within 6 months of
ATAQ-IPF completion, we did not use these variables in
our analyses. All participants gave their written informed
consent to participate.
Outcome measures
ATAQ-IPF
The version (V.2) we used includes 86 items comprising
14 domains: cough (7 items), shortness of breath (SOB;
7 items), planning (6 items), sleep (6 items), mortality
(6 items), energy (6 items), mental health (7 items),
spirituality (6 items), social activities (6 items), ﬁnances
(6 items), independence (6 items), sexuality (5 items),
relationships (6 items) and treatments (6 items).
Response options for each item are arranged on a four-
point scale: 1=‘Strongly disagree’; 2=‘Disagree some-
what’; 3=‘Agree somewhat’ and 4=‘Strongly agree’. Items
in the sexual component have an extra response choice
for ‘Unable to answer’. Summation scoring is used for
each domain and the total score; higher scores connote
greater impairment.
Medical Research Council dyspnoea scale
The Medical Research Council (MRC) scale is a simple
index in which respondents are asked to classify their
dyspnoea. Scores range from 1 to 5, with higher scores
indicating greater dyspnoea. The MRC was used to
broadly classify participants and to examine associations
between dyspnoea level and scores from ATAQ-IPF.
Dyspnoea-12 (D-12)
The D-12 consists of 12 descriptor items, each rated
‘none’ (0), ‘mild’ (1), ‘moderate’ (2) or ‘severe’ (3) and
has been validated for use in IPF.12 13 It provides an
overall score for dyspnoea severity that incorporates
seven physical items and ﬁve affective items. Total scores
range from 0 to 36, with higher scores corresponding to
greater severity. Separate scores for the physical (items
1–7) and affective (items 8–12) may also be calculated.
Study phases and statistical analyses
Item deletion algorithm, Rasch analysis and DIF
Items with responses missing for >20% of the cohort
were deleted. Items with >50% ﬂoor or ceiling effects
were also removed. Remaining items were subjected to
Rasch analysis (separate analyses for each domain).
Items within each domain were tested for ﬁt to the
Rasch model (RUMM2020, http://www.rummlab.com).
Rasch analysis allows an examination of the perform-
ance of individual items and/or groups of items and
permits exploration of the degree to which the require-
ments of construct validity are met.
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Rasch involves an iterative process whereby individual
item ﬁt is assessed, and the impact of item removal on
the item set is reassessed. A number of tests are applied
in this process, including DIF. DIF is a type of bias; here
DIF would be present if subgroups within the sample (eg,
UK vs USA) responded differently to an item despite
having the same levels of HRQL (as measured by their
responses to all items combined). DIF is tested using ana-
lysis of variance (ANOVA), and a statistically signiﬁcant
probability (p<0.05) indicates a DIF problem. Uniform
DIF is characterised by the same constant magnitude of
difference in item function across the continuum of the
construct measured by the scale (here HRQL). That is,
when one group is displaying a consistently greater ability
to afﬁrm an item than another group. In contrast to
uniform DIF, non-uniform DIF represents an interaction
when there is non-uniformity within the differences
between the groups. That is, when the ability afﬁrms an
item is inconsistent among the groups. Consequently, it is
possible with Rasch to examine whether or not a scale
works in the same way for the subgroups deﬁned by
nationality (UK vs USA) by contrasting the response
pattern for each item across nationalities.14 Items with sig-
niﬁcant DIF were deleted from further analyses.
Other item ﬁt statistics that Rasch analysis generates
include ﬁt residuals and χ2 probability statistics.
Residuals represent the amount of deviation from model
expectations and are standardised as z-scores. Residual
z-scores between ±2.5 indicate adequate ﬁt to the
model.15 The χ2 probability statistic tests if there are sig-
niﬁcant differences between observed values and model-
derived, expected values across subgroups with differing
HRQL impairments. A non-signiﬁcant χ2 statistic (p >
0.05) indicates good ﬁt to the model.15 Retained items
within each domain were examined as groups for their
overall ﬁt to the Rasch model by using the item–trait
interaction χ2 statistic, where a non-signiﬁcant p value
(>0.05) indicates ﬁt of the aggregate of items to the
model. We determined Cronbach’s α as a measure of IC
for each domain from the ATAQ-IPF-cA.
Validity assessment of ATAQ-IPF-cA
We used Spearman correlation to test our hypothesis that
there would be moderately strong correlation between
ATAQ-IPF-cA scores and both D-12 and MRC scores in each
of the two nationality-deﬁned subgroups. In this analysis, we
adjusted for multiple comparisons using the Bonferroni
correction method; thus, we considered p≤0.001 to repre-
sent statistical signiﬁcance. We employed known-groups val-
idity, operationalised with ANOVA and p value-adjusted
pairwise comparisons to examine ATAQ-IPF-cA scores
between groups of participants within each subgroup strati-
ﬁed on dyspnoea severity (according to the MRC).
RESULTS
A total of 139 patients participated in this study, 65 from
the UK and 74 from the USA. Baseline characteristics of
the sample are presented in table 1. There was no differ-
ence in mean age or gender distribution between the
subgroups, but FVC% was lower among participants
from the USA. More participants from the USA used
supplemental oxygen, while according to the
dyspnoea-12 (D-12), dyspnoea was greater among partici-
pants from the UK.
Rasch analyses of ATAQ-IPF domains
Table 2 shows which items were removed because of sig-
niﬁcant DIF and which subgroup (UK or USA) was less
likely to strongly agree with each of the deleted items.
Cough
Two of the six items were removed due to ﬂoor effects
(C2: 52% and C4: 51%). Another item demonstrated DIF
and was removed (C6 ‘My cough makes me feel embar-
rassed’, p=0.0003). The remaining four items demon-
strated good ﬁt to the Rasch model (χ2=7.16; p=0.5;
Person Separation Index (PSI)= 0.8) and across severity
levels (ie, item logit locations).
Shortness of breath
Two items were removed due to ceiling effects (SOB9:
51% and SOB14: 71%). The remaining ﬁve items
demonstrated good ﬁt to the Rasch model and were
retained (χ2=18; p=0.6; PSI=0.8).
Planning and analysing
No ﬂoor or ceiling effects were observed. One of the six
items demonstrated signiﬁcant mis-ﬁt to the Rasch
model (PL20: ‘I am able to live my day-to-day life as
carefree as I would like’, χ2; p<0.0001; residual +3.8) and
was removed. One other item (PL16: ‘Before I set out to
do any physical activity, I ﬁnd myself analysing it to see if
it is really something I can do’), was removed to do a
Table 1 Baseline characteristics of sample stratified on
country
UK
n=65
USA
n=74 p Value
Age 69.8±9.2 70.4±8.0 0.44
Male 40 (62) 53 (72) 0.21
FVC% 80.7±18.7
n=55
70.1±17.7
n=70
0.002
DLCO% 42.2±11.9
n=38
43.2±16.5
n=47
0.75
Supplemental O2 11 (18) 38 (51) <0.0001
MRC dyspnoea 0.007
I 2 (3) 1 (1)
II 30 (46) 16 (22)
III 12 (18) 27 (36)
IV 3 (5) 16 (22)
V 18 (28) 14 (19)
Dyspnoea-12 17.0±10.4
n=59
11.6±8.8
n=65
0.002
DLCO, diffusing capacity of the lung for carbon monoxide; FVC,
forced vital capacity; MRC, Medical Research Council.
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high location (logit=0.735) relative to the other items in
the domain. The remaining four items demonstrated
good ﬁt to the Rasch model (χ2=6; p=0.7; PSI=0.77).
Sleep
No ﬂoor or ceiling effects were observed. One item
demonstrated signiﬁcant mis-ﬁt to the Rasch model and
was removed (SL26: ‘I have to take a nap to make it
through the day’; χ2; p=0.01). Good model ﬁt was achieved
with the remaining ﬁve items (χ2=12; p=0.26; PSI=0.7).
Mortality
No ﬂoor or ceiling effects were observed. Two items
(M27 and M32) demonstrated signiﬁcant DIF and were
removed. The remaining four items demonstrated ﬁt to
the Rasch model (χ2=6.5; p=0.58; PSI=0.7).
Energy
No ﬂoor or ceiling effects were observed. One item
(E37: ‘My level of physical energy makes me feel like I
am lazy’) demonstrated DIF (p=0.01) and was removed.
Another item (E35: ‘In the evening time after a normal
day, I have enough energy to do things I world like to
do’) demonstrated mis-ﬁt to the model (χ2=0.001), and
was removed. A good model ﬁt was achieved with the
remaining four items (χ2=116.7; p=0.03; PSI=0.71).
Mental health
No ﬂoor or ceiling effects were observed. One item
(MEN39: ‘I feel weighed down by IPF) demonstrated DIF
(p=0.005) and was removed. Another item (MEN43:
‘Having IPF makes me feel afraid’) was removed due to a
high item location relative to other items in the domain
(logit=0.818). The remaining ﬁve items demonstrated
good model ﬁt (χ2=12; p=0.3; PSI=0.8).
Spirituality
No ﬂoor or ceiling effects were observed. No items
demonstrated signiﬁcant DIF. One item (SPIR47: ‘My
spiritual beliefs bring meaning to my life’) demonstrated
mis-ﬁt to the model (χ2=0.01; residual −3.0) and was
removed. The remaining ﬁve items demonstrated a
good ﬁt to the Rasch model (χ2=6.8; p=0.7; PSI=0.86).
Social activities
No ﬂoor or ceiling effects were observed. No items
demonstrated signiﬁcant DIF. One item (SOC53: ‘I ﬁnd
it difﬁcult to replace activities that I am no longer able
to do because I have IPF’) demonstrated mis-ﬁt to the
model (χ2=0.01) and was deleted. Another item
(SOC54: ‘I ﬁnd it difﬁcult to replace activities that I am
no longer able to do’) was removed due to a high loca-
tion (logit=0.777) relative to the other items. The
remaining four items demonstrated good ﬁt to the
model (χ2=14; p=0.2; PSI=0.72).
Finances
No ﬂoor or ceiling effects were observed. Five of the six
Finance items demonstrated poor ﬁt to the Rasch
model. Three of these items demonstrated signiﬁcant
DIF. Owing to these poor performance characteristics,
this domain was removed.
Independence
No ﬂoor or ceiling effects were observed. One item
(IND64: ‘I occasionally ask for help to do things now
that six months ago I could have done myself’) demon-
strated signiﬁcant DIF (p=0.01) and was removed.
Another item (IND68: ‘Having IPF has forced me to
give up control over my life’) was removed due to misﬁt
Table 2 Items removed because of significant differential item functioning (UK compared with USA)
Domain item
number Item
UK
(logit)
USA
(logit)
Cough 6* My cough disrupts my life 0.51 ✓0.83
Mortality 27† I often worry about how I might die −0.16 ✓0.56
Mortality 32† I am afraid of being maintained at a poor quality of life −1.01 ✓0.13
Energy 37* My level of physical energy makes me feel like I am lazy 0.44 ✓0.69
Mental 39† I feel weighed down by IPF ✓0.39 −0.12
Finances 58* I am concerned that the cost of my care will use up my family’s financial
resources
−0.71 ✓0.61
Finances 61† Having IPF has forced me to reconsider my financial goals ✓0.50 0.02
Finances 62* It has been difficult for me to make the necessary adjustments in my finances
to provide support for my finances
✓0.85 0.75
Independence 4† I occasionally ask for help to do things now that six months ago I could have
done myself
−1.35 ✓−0.38
Relations 76† Living with IPF puts a strain on the relationship I have with member of my
immediate family
✓0.39 0.17
Relations 80† I am less willing to seek and form new relationships because I have IPF −1.25 ✓−0.81
✓=Less likely to respond ‘Strongly Agree’ to the item.
†Uniform differential item functioning.
*Non-uniform differential item functioning.
4 Yorke J, Spencer LG, Duck A, et al. BMJ Open Resp Res 2014;1:e000024. doi:10.1136/bmjresp-2014-000024
Open Access
 group.bmj.com on May 18, 2014 - Published by bmjopenrespres.bmj.comDownloaded from 
to the model (p=0.02). The remaining four items
demonstrated good model ﬁt (χ2=13; p=0.1; PSI=0.68).
Sexuality
Owing to the high response rate for the ‘unable to
answer’ option, it was not possible to conduct analyses
on items in this domain. The responses for ‘unable to
answer’ ranged from 14% to 38%. This domain was
removed in total.
Relationships
One item was removed due to a ﬂoor effect (REL77: ‘I
am satisﬁed with the current state of my relationships’,
52%). The remaining ﬁve items demonstrate poor ﬁt to
the Rasch model (χ2=27; p<0.001; PSI=0.40), including
items REF76 and REL80 which also demonstrated sig-
niﬁcant DIF. This domain was removed.
Treatments
Four items had a high level of missing data (19–20%)
and were removed. Another item (Rx84: ‘Having to use
supplemental oxygen decreases a person’s quality of
life’) demonstrated a ﬂoor effect (54%). Consequently,
the Treatments domain was removed.
Table 3 shows some of the performance characteristics
of domains on the ATAQ-IPF-cA.
Validity assessment of ATAQ-IPF-cA
The ﬁnal ATAQ-IPF-cA contained 43 items and 10 com-
ponents with a total score ranging from 43 to 172.
Table 4 contains correlation coefﬁcients showing the
strength of the association between ATAQ-IPF-cA scores
and the D-12 and MRC. On balance, the pattern and
strength of associations was similar across countries. For
two domains, (Sleep and Mortality), correlations were
signiﬁcant for one subgroup but not the other; while,
for six domains and the total score, correlations were sig-
niﬁcant (and in the same direction) for the UK and
USA subgroups. For the D-12, for each subgroup, the
strongest correlations were, as hypothesised, with the
SOB domain and the total score.
Figure 1 shows boxplots for ATAQ-IPF-cA total scores
by MRC class for each country-speciﬁc subgroup. Only
two participants from the UK and one from the USA
were in MRC class 1, so within each country subgroup,
we compared ATAQ-IPF-cA scores from participants in
MRC class 2 with those in MRC class 5. For participants
from the UK, the difference in ATAQ-IPF-cA total score
between these two MRC classes was 30.90 (95% CI 6.71
to 55.10), and for participants from the USA, the differ-
ence was 32.58 (95% CI 3.47 to 61.68).
DISCUSSION
In this study, we examined items and domains of
ATAQ-IPF for their performance between participants
from the UK and USA, deleted poorly performing items
and retained the remainder to generate a cross-Atlantic
version of ATAQ-IPF, the ATAQ-IPF-cA. ATAQ-IPF-cA is a
shorter questionnaire with very good measurement
properties, including invariance across countries.
Table 3 Internal consistency and floor and ceiling effects
of ATAQ-IPF-cA
Domain
Internal
consistency
Percentage
at floor/ceiling
Cough 0.92 25/4
Shortness of breath 0.82 5/5
Planning 0.89 12/10
Sleep 0.74 2/3
Mortality 0.81 10/4
Spirituality 0.93 17/7
Energy 0.79 2/12
Mental health 0.89 8/7
Social 0.77 8/9
Independence 0.82 12/7
ATAQ-IPF-cA, A Tool to Assess Quality of Life in Patients with
Idiopathic Pulmonary Fibrosis cross-Atlantic version.
Table 4 Correlations between ATAQ-IPF scores and markers of IPF severity
D12 MRC
UK USA UK USA
Cough 0.26 (0.05) 0.34 (0.007) −0/06 (0.64) 0.12 (0.30)
SOB 0.78 (<0.0001) 0.71 (<0.0001) 0.53 (<0.0001) 0.62 (<0.0001)
Planning 0.53 (<0.0001) 0.57 (<0.0001) 0.65 (<0.0001) 0.54 (<0.0001)
Sleep 0.48 (0.0003) 0.20 (0.13) 0.33 (0.01) 0.11 (0.37)
Mortality 0.29 (0.03) 0.49 (<0.0001) 0.14 (0.25) 0.18 (0.13)
Energy 0.61 (<0.0001) 0.61 (<0.0001) 0.48 (<0.0001) 0.38 (0.001)
Mental health 0.68 (<0.0001) 0.55 (<0.0001) 0.40 (0.001) 0.40 (0.0005)
Spirituality −0.04 (0.78) 0.10 (0.43) 0.06 (0.62) 0.22 (0.06)
Social 0.50 (<0.0001) 0.57 (<0.0001) 0.55 (<0.0001) 0.49 (<0.0001)
Independence 0.69 (<0.0001) 0.57 (<0.0001) 0.60 (<0.0001) 0.48 (<0.0001)
ATAQ total 0.75 (<0.0001) 0.70 (<0.0001) 0.56 (<0.0001) 0.55 (<0.0001)
ATAQ, A Tool to Assess Quality of Life in Patients with Idiopathic Pulmonary Fibrosis; D12, dyspnoea-12; IPF, idiopathic pulmonary fibrosis;
MRC, Medical Research Council breathlessness scale; SOB, shortness of breath.
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Items within each domain of ATAQ-IPF-cA had good
ﬁt to the Rasch model, verifying that clusters of items
composing a given domain indeed tap a single con-
struct. The IC reliability of each ATAQ-IPF-cA domain
was at least as good as those for the original ATAQ-IPF,
and in this two-country sample, exhibited minimal ﬂoor
or ceiling effects. Further, as we had hoped, the retained
43 items span a broad range of severities across the
HRQL scale. This means the ATAQ-IPF-cA should
capture baseline and changes in HRQL in patients with
IPF who have very poor or very good HRQL (and all
levels in between).
It is well known that questionnaire items do not always
function equally in different groups—such as responders
from different countries. If that were the case, the item
set for all groups analysed together would fail to meet
criteria for the Rasch model, or items would demon-
strate signiﬁcant DIF. Thus, Rasch analysis provides an
excellent method to test items and identify those that
either require modiﬁcation to be retained or that
should be deleted to improve instrument performance.
Thus, by using Rasch methodology, we were able to
select items that generate the most precise measurement
of HRQL (among the pool of items on ATAQ-IPF) and
that meet a fundamental assumption of the Rasch
model: that each item contributes reliably to the meas-
urement of the single underlying construct, regardless
of country location.
To a certain degree, IC of an item set (eg, those com-
posing a domain) depends on item number—a greater
number of items will inﬂate the IC coefﬁcient. We were
prepared to observe drops in the IC coefﬁcients of
domains as items were removed, but compared with α
previously reported for ATAQ-IPF, those for
ATAQ-IPF-cA were as high or higher. The construct valid-
ity of ATAQ-IPF-cA was supported by the numerous sig-
niﬁcant correlations (for both USA and UK subgroups)
between domain scores and scores from other PROs that
measure dyspnoea, the main driver of HRQL in patients
with IPF. For D-12 scores, we observed the strongest cor-
relations with ATAQ-IPF-cA total and SOB domain
scores in both the UK and USA subgroups. This is not
surprising since the D-12 has previously demonstrated
excellent measurement properties in IPF.13 16
We removed three domains altogether: Sexuality,
Relationships and Finances. The Sexuality domain was
removed due to missing responses, and a particularly
high number of responses of ‘not able to answer’.
Chronic illness can have profound negative effects on
relationships and sexual satisfaction of both patients and
partners.17 The average age of our population was
70 years and not all participants were in a relationship
with a signiﬁcant other. These factors may have contrib-
uted to the response patterns observed in this study.
Likewise, chronic illness can impact relationships
between patients and their friends, and most assuredly,
loved ones in the same household.18 The results of our
analyses suggest that more work is needed to develop a
tool that can precisely assess that impact among patients
with IPF in different countries. Given the differences in
the provision of healthcare and related ﬁnances
between the UK and USA, it is not surprising to ﬁnd dif-
ferences in participant responses to items in the
Finances domain. We found that participants from the
UK were more likely to respond positively to
ﬁnance-related items despite receiving free healthcare
through the UK National Health Service. However, due
to invariance in responses between the two countries
this component was deleted.
The results of this study, while demonstrating cross-
cultural validity of the ATAQ-IPF-cA, highlight the pre-
ferred option to develop questionnaires intended for
international use in the target countries from the outset.
This would enable the early detection of items with sig-
niﬁcant DIF and the ability to adapt an iterative process
of checking for DIF and scale content during initial
Figure 1 ATAQ-IPF-cA total
scores between country-specific
subgroups by MRC class.
ATAQ-IPF-cA, A Tool to Assess
Quality of Life in Idiopathic
Pulmonary Fibrosis Cross-Atlantic
version.
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development as opposed to post hoc. However, such an
approach would require signiﬁcant resources which are
not always available during the embryotic stages of
instrument.
We found no other studies examining cross-cultural
aspects of HRQL outcomes using DIF in IPF. As such it
is not known whether the illness experience between
patients with IPF in the USA and UK are different—we
observed DIF in 11 ATAQ-IPF items so it can be
assumed that previous international studies examining
HRQL in IPF may have unwittingly included instruments
that contain items that are violating the requirement of
unidimensionality.19 Responses to a scale’s items should
only depend on the severity of HRQL and not on exter-
nal factors, such as cultural background and, for
example, healthcare provision.
This study has limitations. Owing to the absence of
data, we were unable to examine correlations between
pulmonary physiology values and ATAQ-IPF-cA scores in
the UK subgroup. We were able to run these analyses in
the USA subgroup, and as hypothesised, there were
moderate correlations between pulmonary physiology
values and the majority of ATAQ-IPF-cA domain scores.
Participants were recruited from specialty clinics, so the
results here may not be applicable to the more general
population with IPF in either country. Given the lack of
longitudinal data, we are unable to comment on the per-
formance of the retained items. Although there were dif-
ferences between groups in baseline characteristics, a
basic tenet of Rasch analysis assures that items meeting
Rasch model requirements contribute reliably to the
measurement of the one underlying construct (here it is
HRQL) in all respondents, regardless of underlying dif-
ferences in health status or other variables.
In conclusion, we used a systematic, statistically based
method to revise the original ATAQ-IPF and develop a
version that is relevant to both USA and UK patient
populations. The reliability and validity of the
ATAQ-IPF-cA are acceptable and comparable to the ori-
ginal instrument. Prospective studies will determine
whether the speciﬁcity of the m-ATAQ-IPF is responsive
to underlying change in patients with IPF.
Author affiliations
1School of Nursing, Midwifery and Social Work, University of Manchester,
Manchester, UK
2University Hospital of South Manchester Foundation Trust, Manchester, UK
3Aintree University Hospital NHS Foundation Trust, Liverpool, UK
4School of Nursing, Midwifery, Social Work and Social Sciences, University of
Salford, Salford, UK
5Pennine Acute NHS Hospitals Trust, Fairfield General Hospital, Bury, UK
6Intensive Care Unit, North Manchester General Hospital, Manchester, UK
7Autoimmune Lung Center and Interstitial Lung Disease Program, National
Jewish Health, , Denver, Colorado, USA
Contributors JJS and JY conceptualised the study. JJS, JY, LGS, AD, SR,
GNK, MSL and AM participated in data collection. JJS and JY participated in
data analysis. All the authors participated in interpretation of the results of
data analysis, manuscript preparation and editing and approval of the final
manuscript.
Funding This study was supported in part by the British Lung Foundation
and the NIH (K23 HL092227), BLF (TC08/6).
Competing interests None.
Ethics approval This study was approved by the National Jewish Health
Institutional Review Board (#HS 2609) and the Salford & Trafford Local
Research Ethics Committee (#09/H1004/2).
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement No additional data are available.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/3.0/
REFERENCES
1. Raghu G, Collard H, Egan J, et al. An official ATS/ERS/JRS/ALAT
statement: idiopathic pulmonary fibrosis: evidence-based guidelines
for diagnosis and management. Am J Respir Crit Care Med
2011;183:788–824.
2. Gribbin J, Hubbard RB, Le Jeune I, et al. Incidence and mortality of
idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax
2006;61:980–5.
3. Schoenheit G, Becattelli I, Cohen AH. Living with idiopathic
pulmonary fibrosis: an in-depth qualitative survey of European
patients. Chron Respir Dis 2011;8:225–31.
4. Swigris JJ, Stewart AL, Gould MK, et al. Patients’ perspectives on
how idiopathic pulmonary fibrosis affects the quality of their lives.
Health Qual Life Outcomes 2005;3:61.
5. Ware J Jr, Sherbourne C. The MOS 36-item short-form health
survey (SF-36). I. Conceptual framework and item selection. Med
Care 1992;30:473–83.
6. Jones PW, Quirk FH, Baveystock CM. The St George’s Respiratory
Questionnaire. Respir Med 1991;85(Suppl B):25–31; discussion
33–27.
7. Swigris JJ, Wilson SR, Green KE, et al. Development of the
ATAQ-IPF: a tool to assess quality of life in IPF. Health Qual Life
Outcomes 2010;8:77.
8. Johnson T, Kulesa P, Llc I, et al. The relation between culture and
response styles: evidence from 19 countries Timothy Johnson.
J Cross Cult Psychol 2005;36:264–77.
9. American Thoracic Society. Standardization of spirometry, 1994
update. Am J Respir Crit Care Med 1995;152:1107–36.
10. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of
spirometry. Eur Respir J 2005;26:319–38.
11. Crapo R, Morris A. Standardized single breath normal values for
carbon monoxide diffusing capacity. Am Rev Respir Dis
1981;123:185–9.
12. Yorke J, Moosavi SH, Shuldham C, et al. Quantification of dyspnoea
using descriptors: development and initial testing of the
Dyspnoea-12. Thorax 2010;65:21–6.
13. Yorke J, Swigris J, Russell AM, et al. Dyspnea-12 is a valid and
reliable measure of breathlessness in patients with interstitial lung
disease. Chest 2011;139:159–64.
14. Brodersen J, Meads D, Kreiner S, et al. Methodological aspects of
differential item functioning in the Rasch model. J Medical
Economics 2007;10:309–24.
15. Pallant JF, Tennant A. An introduction to the Rasch measurement
model: an example using the Hospital Anxiety and Depression Scale
(HADS). Br J Clin Psychol 2007;46:1–18.
16. Swigris JJ, Yorke J, Sprunger DB, et al. Assessing dyspnea and its
impact on patients with connective tissue disease-related interstitial
lung disease. Respir Med 2010;104:1350–5.
17. McInnes RA. Chronic illness and sexuality. Med J Aust
2003;179:263–6.
18. Belkin A, Albright K, Swigris J. A qualitative study of informal
caregivers’ perspectives on the effects of idiopathic pulmonary
fibrosis. BMJ Open Resp Res 2013;1:e000007.
19. Tennant A, Penta M, Tesio L, et al. Assessing and adjusting for
cross-cultural validity of impairment and activity limitation scales
through differential item functioning within the framework of the
Rasch model: the PRO-ESOR project. Med Care 2004;42:I37–48.
Yorke J, Spencer LG, Duck A, et al. BMJ Open Resp Res 2014;1:e000024. doi:10.1136/bmjresp-2014-000024 7
Open Access
 group.bmj.com on May 18, 2014 - Published by bmjopenrespres.bmj.comDownloaded from 
doi: 10.1136/bmjresp-2014-000024
 2014 1: BMJ Open Resp Res
 
Janelle Yorke, Lisa G Spencer, Annette Duck, et al.
 
(ATAQ-IPF-cA)
Idiopathic Pulmonary Fibrosis
of the A Tool to Assess Quality of Life in 
Cross-Atlantic modification and validation
 http://bmjopenrespres.bmj.com/content/1/1/e000024.full.html
Updated information and services can be found at: 
These include:
References
 http://bmjopenrespres.bmj.com/content/1/1/e000024.full.html#ref-list-1
This article cites 19 articles, 5 of which can be accessed free at:
Open Access
non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/
terms, provided the original work is properly cited and the use is
work non-commercially, and license their derivative works on different 
license, which permits others to distribute, remix, adapt, build upon this
Creative Commons Attribution Non Commercial (CC BY-NC 3.0) 
This is an Open Access article distributed in accordance with the
service
Email alerting
the box at the top right corner of the online article.
Receive free email alerts when new articles cite this article. Sign up in
Notes
 http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
 http://journals.bmj.com/cgi/reprintform
To order reprints go to:
 http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
 group.bmj.com on May 18, 2014 - Published by bmjopenrespres.bmj.comDownloaded from 
